Blog
RSS FeedPosted by Michael Wonder on 02 May 2017
Addressing bias and conflict of interest among biomedical researchers
2 May 2017 - Bias in research is ubiquitous and the goal of every researcher should be to reduce bias and ...
Posted by Michael Wonder on 02 May 2017
Budget 2017: Peak GP body supports Government's generic drug scheme but medical community split
2 May 2017 - Australia's peak GP group has come out in support of a government proposal to encourage doctors ...
Posted by Michael Wonder on 01 May 2017
Cancer fund failure highlights the dilemma of drug pricing
1 May 2017 - The challenge is to keep treatments affordable but still encourage innovation. ...
Posted by Michael Wonder on 01 May 2017
Budget 2017: doctors reject changes on generic drugs which could save almost $2 billion
1 May 2017 - Australians will increasingly find themselves prescribed generic drugs rather than the big-name brands, under changes to ...
Posted by Michael Wonder on 01 May 2017
‘Basic Bronze’ proposal to cut health insurance premiums
1 May 2017 - Health funds would be compelled to offer a standard, low-cost insurance policy under a proposal being ...
Posted by Michael Wonder on 01 May 2017
NICE u-turn recommends some access to Takeda’s Adcetris
28 April 2017 - It is now looking likely that some patients with relapsed/refractory Hodgkin's lymphoma will be able to ...
Posted by Michael Wonder on 01 May 2017
Making $310 million of new vital drugs available for Australian patients
1 May 2017 - The Australian Government is continuing to subsidise more life-changing and life-saving drugs on the Pharmaceutical Benefits Scheme ...
Posted by Michael Wonder on 01 May 2017
Cystic fibrosis 'miracle' drug among Turnbull government's $310 million PBS listing
1 May 2017 - A cystic fibrosis "miracle" drug that would normally cost patients $300,000 a year and a breakthrough ...
Posted by Michael Wonder on 30 Apr 2017
Schedule of Pharmaceutical Benefits - 1 May 2017
1 May 2017 - The 1 May 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 30 Apr 2017
Agenda for 3 May 2017 TC meeting
28 April 2017 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 30 Apr 2017
New Zealand Pharmaceutical Schedule - 1 May 2017 update
1 May 2017 - The May 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 29 Apr 2017
Cancer Drugs Fund condemned as expensive and ineffective
28 April 2017 - Treatments approved by David Cameron’s scheme were not worth money, extended life very little and often had ...
Posted by Michael Wonder on 29 Apr 2017
Decision to list 5-aminolevulinic acid hydrochloride (Gliolan) on the Hospital Medicines List
28 April 2017 - PHARMAC is pleased to announce that the approval of an agreement with Specialised Therapeutics Limited for ...
Posted by Michael Wonder on 27 Apr 2017
NICE recommends Amgen's Blincyto (blinatumomab) for adults with relapsed or refractory Philadelphia chromosome negative B-precursor acute lymphoblastic leukaemia
27 April 2017 - FAD reinforces significant need for innovative treatment options for patients with relapsed or refractory acute lymphoblastic ...
Posted by Michael Wonder on 27 Apr 2017
Cancer care drug costs concern group
26 April 2017 - Jennifer McGrady has never even touched a cigarette. ...